Literature DB >> 2463933

Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors.

O G Ottmann1, M Abboud, K Welte, L M Souza, L M Pelus.   

Abstract

Recombinant human interleukin 3 (IL3) produced in Escherichia coli was purified and its activities examined in cultures of highly enriched human bone marrow progenitor cells. Human IL3 stimulated multipotential (CFU-GEMM) and erythroid (BFU-E) progenitor cells, generating 95% more BFU-E than recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). No further enhancement of BFU-E or CFU-GEMM occurred when IL3 and GM-CSF were used in combination. Human IL3 was more effective than GM-CSF in stimulating granulocyte-macrophage colony-forming cells (CFU-GM) in short-term suspension cultures, but did not induce an increase of CFU-GM, BFU-E, or CFU-GEMM above input levels. IL3 was more active on day-14 (d14) than on d7 CFU-GM, similar to GM-CSF, but generated fewer and smaller CFU-GM-derived clones than either GM-CSF or granulocyte CSF (CI-CSF). The simultaneous addition of plateau levels of IL3 and GM-CSF resulted in an infra-additive augmentation of d7 and d14 CFU-GM-derived clones, whereas IL3 and G-CSF enhanced the number and cellularity predominantly of d14 CFU-GM. In liquid cultures, IL3 induced a greater than 100-fold increase in the number of basophil-mast-like cells and eosinophils and allowed maintenance of these cultures for up to 7 weeks. Human GM-CSF was an almost equally potent, stimulus of eosinophil development but had only a marginal effect on basophilic precursors, whereas G-CSF lacked both activities. Therefore, human IL3 is a multilineage hemopoietic growth factor whose activities appear to encompass and extend beyond those of GM-CSF.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2463933

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  Effects of various recombinant human hemopoietic growth factors (rhEpo, rhG-CSF, rhGM-CSF, rhIl-3) on the growth of peripheral blood progenitor cells (BFU-E, CFU-GM).

Authors:  S Serke; D Huhn
Journal:  Blut       Date:  1990-07

3.  Preclinical studies and future directions in the development of new hematologic growth factors.

Authors:  S Gillis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

Review 4.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

5.  Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.

Authors:  A P Gillio; C Gasparetto; J Laver; M Abboud; M A Bonilla; M B Garnick; R J O'Reilly
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.

Authors:  G J Veldhuis; P H Willemse; J H Beijnen; H Boonstra; H Piersma; W T van der Graaf; E G de Vries
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 7.  Increasing hematopoietic stem cell yield to develop mice with human immune systems.

Authors:  Juan-Carlos Biancotti; Terrence Town
Journal:  Biomed Res Int       Date:  2013-02-14       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.